葵花药业: 关于全资孙公司广东葵花医药有限公司减资进展公告

Summary of Key Points Core Viewpoint - The company,葵花药业集团股份有限公司, has decided to reduce the registered capital of its wholly-owned subsidiary, 广东葵花医药有限公司, from RMB 43 million to RMB 38 million, reflecting a strategic financial adjustment [1]. Group 1: Capital Reduction Overview - The company has proposed a capital reduction plan for its subsidiary, 广东葵花, reducing its registered capital from RMB 43 million to RMB 38 million [1]. - The announcement regarding the capital reduction was disclosed on April 25, 2025, on the 巨潮资讯网 [1]. Group 2: Progress of Capital Reduction - The capital reduction process has been completed, and 广东葵花 has received a new business license from the Guangzhou Baiyun District Market Supervision Administration [1]. - The updated business license reflects the new registered capital amount [1]. Group 3: Reference Documents - The company has made the relevant documents available for review as part of the announcement [1].